The launch of Neffy by ARS Pharmaceuticals, under the ticker SPRY, marks a significant innovation in the treatment of severe allergic reactions. The fact that it is the first FDA-approved needle-free epinephrine nasal spray and that its early sales have exceeded expectations suggests strong market acceptance and potential for high revenue growth. The possibility of Neffy becoming an OTC medication further expands its market reach, contributing to a multibillion-dollar total addressable market. These factors are likely to positively impact SPRY's stock price in the short term.